Pharmac funds type 2 DM drug, sets 3-year funding path

Author：

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.461, 2004-01, pp. : 11-11

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

NZ Pharmac funds new treatments

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 628, 2011-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

Pharmac announces new funding decisions

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 618, 2010-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

Pioglitazone the answer to managing type 2 DM in Europe?

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 343, 2001-01 ,pp. : 789-789

Adis International

Access to resources Recommend Favorite

New Zealand's drug subsidy agency, Pharmac, is to fund trastuzumab for HER2-positive early breast cancer.

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 530, 2007-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

Adding a thiazolidinedione a valid option in type 2 DM

Inpharma, Vol. 1, Iss. 1434, 2004-01 ,pp. : 17-17

Adis International

Access to resources Recommend Favorite